Tuberculosis: Multidrug-resistant (MDR-TB) or rifampicin-resistant TB …
2024年5月20日 · Multidrug-resistant TB (MDR-TB) is a form of TB disease caused by a strain of M. tuberculosis complex that is resistant to rifampicin and isoniazid. Globally, an estimated 410 000 people (95% UI: 370 000–450 000) developed multidrug- or rifampicin-resistant tuberculosis (MDR/RR-TB) in 2022.
Publication Item - World Health Organization (WHO)
The WHO Consolidated Guidelines on Tuberculosis (TB), Module 4: Treatment - Drug-Resistant Tuberculosis Treatment 2022 update informs health care professionals in Member States on how to improve treatment and care for patients with drug-resistant TB (DR-TB).
TB strains may be susceptible or resistant to isoniazid (i.e. MDR-TB), or resistant to other first-line TB medicines (polyresistant) or second-line TB medicines (e.g. extensively drug-resistant [XDR]-TB). In these guidelines and elsewhere, MDR-TB and …
2.4 Drug-resistant TB treatment - World Health Organization (WHO)
Estimated levels of treatment coverage for MDR/RR-TB in 2022, approximated as the number of people enrolled on treatment for MDR-TB in 2022 divided by the estimated number of people who developed MDR/RR-TB (incident cases) in 2022 and expressed as a percentage, remain low: globally, 43% in 2022 (Fig. 2.4.5).The WHO regions with the highest levels of treatment coverage are the African Region ...
Module 4: Drug-resistant tuberculosis treatment, 2022 update | TB ...
Commonly used terms and key definitions in DR-TB treatment. 3. Key considerations in DR-TB treatment. 4. The 6-month bedaquiline, pretomanid, linezolid and moxifloxacin (BPaLM) regimen. 5. The 9-month all-oral regimen. 6. The longer regimens. 7. Regimen for rifampicin susceptible and isoniazid resistant TB. 8. Adjuncts to MDR-TB treatment. 9.
About 410,000 new cases of multidrug-resistant1 or rifampicin-resistant tuberculosis (MDR/RR-TB) were estimated to occur in 2022. While all of these would have been eligible for a second-line TB treatment regimen, only 175,650 enrolments on treatment were reported by …
In multidrug- or rifampicin-resistant tuberculosis (MDR/RR-TB) patients on longer regimens, all three Group A agents and at least one Group B agent should be included to ensure that treatment starts with at least four TB agents likely to be effective and that at least three agents are included for the rest of the treatment if bedaquiline is stop...
Introduction | TB Knowledge Sharing
This current module on DR-TB treatment provides specific recommendations on the treatment of DR-TB, including use of regimens for rifampicin-susceptible, isoniazid-resistant TB (Hr-TB), all-oral shorter regimens for MDR/RR-TB, longer regimens for MDR/RR-TB, monitoring patient response to MDR/RR-TB treatment, starting ART in patients on second ...
1.3 Drug-resistant TB - World Health Organization (WHO)
Most attention has been given to the proportion of people diagnosed with TB who have rifampicin-resistant TB (RR-TB) and multidrug-resistant TB (MDR-TB, defined as resistance to both rifampicin and isoniazid), collectively referred to as MDR/RR-TB …
Executive summary - WHO consolidated guidelines on drug …
The consolidated guidelines include policy recommendations on treatment regimens for isoniazid-resistant TB and multidrug- and rifampicin-resistant , including longer and shorter regimens for MDR/RR-TB, culture monitoring of patients on treatment, the timing of antiretroviral therapy in MDR/RR-TB patients infected with the human ...